<DOC>
	<DOCNO>NCT00732992</DOCNO>
	<brief_summary>This study assess combination sunitinib pemetrexed tolerable coadministered recommended dose/schedule .</brief_summary>
	<brief_title>A Safety Study Of Sunitinib In Combination With Pemetrexed In Patients With Advanced Solid Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Patients diagnosis solid malignancy refractory standard therapy standard therapy exists . Patients good performance status ( ECOG 0 1 ) Prior treatment either pemetrexed SU011248 . Coughing blood within 4 week start study treatment ( small amount okey ) . Hypertension control medication .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>Solid tumor</keyword>
	<keyword>malignancy</keyword>
	<keyword>sunitinib</keyword>
	<keyword>pemetrexed</keyword>
	<keyword>phase 1</keyword>
	<keyword>neoplasm</keyword>
</DOC>